FDA Novo Nordisk - Search News

Ozempic receives FDA nod for treating chronic kidney disease

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

The Baltimore Sun · 24m

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

8hon MSN

Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...

9don MSN

Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

6don MSN

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk says it has not yet posted details about new CagriSema trial

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results